Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.54 |
| ▸ | JAK3 | P52333 | 15/20 | 0.54 |
| ▸ | JAK1 | P23458 | 14/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054902 | 0.85 | JAK2 (0.55) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL2054903 | 0.85 | JAK2 (0.55) | JAK2JAK3JAK1ALDH1A1 | |
| SCHEMBL14628869 | 0.85 | JAK2 (0.55) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL2054899 | 0.83 | JAK2 (0.61) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL2054897 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL2054915 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1 | |
| SCHEMBL2054925 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL2054884 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1ALDH1A1 | |
| SCHEMBL2054922 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1TYK2 | |
| SCHEMBL2054927 | 0.83 | JAK2 (0.53) | JAK2JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | JAK2 2/4885JAK3 1/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.